

EQA round: KM1/24 - Cardiac Markers

Deadline: 9.2.2024

Setup: Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1														
(218) CK-MB mass	[µg/L]				10							8	8	100
Sample A1		47,2	7,7	16	10							8	8	100
(60) Roche		44,4	1	2,3	5	0	CVPG	43,5	1,8	27%	31,7	55,3	5	
Other					5	0							3	
							1x 1, 2x 12, 1x 61, 1x 179							
Sample B1		4,13	0,73	18	10							8	8	100
(60) Roche		4,43	0,39	8,7	5	0	CVPG	4,42	0,22	27%	3,22	5,62	5	
Other					5	0							3	
							1x 1, 2x 12, 1x 61, 1x 179							
(444) Homocysteine	[µmol/L]				26							22	21	95
Sample A1		18,3	2,1	12	26							22	21	95
(60) Roche		19,6	0,37	1,9	5	0	CVPG	19,7	0,37	20%	15,7	23,7	5	
(109) Axis-Shield		18,9	1,5	8,1	11	0	CVPG	18,7	0,83	20%	14,9	22,5	11	
Other					10	0							6	
							4x 1, 1x 58, 1x 75, 2x 179, 2x 999							
Sample B1		12,8	1,6	12	26							22	21	95
(60) Roche		13,7	0,22	1,6	5	0	CVPG	13,6	0,19	20%	10,8	16,4	5	
(109) Axis-Shield		13	1,1	8,5	11	0	CVPG	12,9	0,61	20%	10,3	15,5	11	
Other					10	0							6	
							4x 1, 1x 58, 1x 75, 2x 179, 2x 999							
(441) Myoglobin	[µg/L]				26							24	23	96
Sample A1		255	20	7,8	26							24	23	96
(60) Roche		256	14	5,4	16	0	CVPG	255	4,1	22%	198	312	16	
Other					10	0							8	
							3x 843, 1x 1, 3x 12, 2x 178, 1x 179							
Sample B1		32,1	3	9,4	26							24	23	96
(60) Roche		32,1	2,2	6,8	16	0	CVPG	31,8	0,79	22%	24,8	38,8	16	
Other					10	0							8	
							3x 843, 1x 1, 3x 12, 2x 178, 1x 179							
(447) NT-proBNP	[ng/L]				50							46	45	98
Sample A1		2720	310	11	50							46	45	98
(1) Abbott		2880	140	4,8	7	0	CVPG	2960	53	27%	2160	3760	7	
(60) Roche		2580	100	4	34	0	CVPG	2540	35	27%	1850	3230	34	
Other					9	0							5	
							1x 12, 2x 15, 2x 54, 2x 61, 1x 73, 1x 179							
Sample B1		213	16	7,7	50							46	45	98
(1) Abbott		213	17	7,9	7	0	CVPG	216	5,2	27%	157	275	7	
(60) Roche		206	9,3	4,5	34	0	CVPG	201	2,6	27%	146	256	34	
Other					9	0							5	
							1x 12, 2x 15, 2x 54, 2x 61, 1x 73, 1x 179							
(442) Troponin I	[ng/L]				17							15	15	100
Sample A1		229	180	80	17							15	15	100
(12) Beckman Coulter		117	6,7	5,8	8	0	CVPG	118	3,7	27%	86,1	150	8	
Other					9	0							7	
							4x 1, 1x 54, 1x 73, 2x 179, 1x 999							
Sample B1		27,6	6,9	25	17							15	15	100
(12) Beckman Coulter		28,4	1,3	4,4	8	0	CVPG	28,1	0,95	27%	20,5	35,7	8	
Other					9	0							7	
							4x 1, 1x 54, 1x 73, 2x 179, 1x 999							
(443) Troponin T	[ng/L]				38							36	35	97
Sample A1		1720	110	6,2	38							36	36	100
(2) Immunochemical methods (hs); (60) Roche		1720	100	6	36	0	CVPG	1760	27	22%	1370	2150	36	
Other					2	0							0	
							1x 1/60, 1x 1/61							
Sample B1		16,9	2,4	14	38							36	35	97
(2) Immunochemical methods (hs); (60) Roche		17,1	2,4	14	36	0	CVPG	17,2	0,42	22%	13,4	21	36	
Other					2	0							0	
							1x 1/60, 1x 1/61							
Set 2														
(449) BNP	[ng/L]				3							1	1	100
Sample A2					3							1	1	100
Other					3	0							1	
							1x 1, 1x 12, 1x 179							

EQA round: KM1/24 - Cardiac Markers

Deadline: 9.2.2024

Setup: Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Sample B2												1	1	100
Other					3	0						1		
							1x 1, 1x 12, 1x 179							